Eosinophilia in Patients with Asthma: A Sign of Eosinophilic Granulomatosis with Polyangiitis (EGPA)?

To participate in this activity, please start here:

Welcome to this overview of eosinophilic granulomatosis with polyangiitis with Michael Wechsler, MD. In this activity, Dr. Wechsler reviews the pathogenesis, diagnosis, prognosis, and treatment of EGPA. This presentation will help you recognize EGPA and differentiate it from other diagnoses and other small-vessel vasculitides, and develop treatment plans based on the patient’s prognosis and response to first-line treatments.

Want to learn more?
Visit Part 2 of this two-part educational series to learn about diagnosis, prognosis, and treatment of EGPA.

Course Credit:

1.00 AANP Contact Hour
1.00 AMA PRA Category 1 CreditTM

Dates:

Opens: 2020-07-31
Closes: 2021-07-30

Target Audience:

This activity was developed for allergist/immunologists, rheumatologists, pulmonologists, hematologists, dermatologists, cardiologists, EENT specialists and other clinicians involved in the care of patients with EGPA.

This educational activity is supported by an educational grant from GlaxoSmithKline.
Complete CME Details
  • Michael Wechsler, MD

    Professor of Medicine
    Director, NJH Cohen Family Asthma Institute
    Department of Medicine
    National Jewish Health
    Denver, Colorado

Learning Objectives

  • Discuss the clinical signs and symptoms that support a diagnosis of EGPA
  • Describe the clinical progression of EGPA
  • Classify patients’ risk based on disease activity and the presence of ANCA
  • Select an appropriate therapy for EGPA based on patient’s disease activity and characteristics

Faculty Disclosures

Michael Wechsler, MD

Consultant                   

  • AstraZeneca – clinical area: Asthma/EGPA
  • Equillium – clinical area: Asthma
  • Genentech – clinical area: Asthma
  • Genzyme – clinical area: Asthma
  • GlaxoSmithKline – clinical area: Asthma/EGPA
  • Regeneron – clinical area: Asthma
  • Restorbio – clinical area: Asthma
  • Sanofi – clinical area: Asthma
  • Teva – clinical area: Asthma

Speakers bureau 

  • AstraZeneca – clinical area: Asthma/EGPA
  • GlaxoSmithKline – clinical area: Asthma/EGPA
  • Sanofi – clinical area: Asthma

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to 1.00 contact hour. Program ID# 5825-EM1.

Additional Content Planners

Juan Cardet, MD (Peer Reviewer)
No significant relationships to disclose.

Chris Fischer, MSc (Medical Writer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Nurse Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.